SEC Form 4	
------------	--

П

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

## OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Addre Arnold Charl		son*	2. Issuer Name and Ticker or Trading Symbol ANI PHARMACEUTICALS INC [ ANIP ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
(Last) (First) (Middle) C/O ANI PHARMACEUTICALS, INC. 210 MAIN STREET WEST			3. Date of Earliest Transaction (Month/Day/Year) 05/22/2014	- X	Officer (give title below) VP and C	Other (specify below) FO		
(Street) BAUDETTE (City)	MN (State)	56623 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	vidual or Joint/Group Filir Form filed by One Rep Form filed by More the Person	oorting Person		

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported		7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)
Common Stock <sup>(1)</sup>	05/22/2014		Α		6,000	Α	\$ <mark>0</mark>	66,385	D	

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		of Derivati Securiti Acquire (A) or Dispose of (D) (I	Derivative (Month/Day/Year) Decurities Acquired		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to Purchase	\$6.36	05/22/2014 <sup>(2)</sup>		Α		44,333		(3)	07/11/2023	Common Stock	44,333	\$0	44,333	D	

#### Explanation of Responses:

1. On April 1, 2014, the Board of Directors of the Issuer approved the grant of restricted stock, which vests in equal annual installments on the first, second, third and fourth anniversaries of the date of grant. The award was made contingent upon receipt by the Issuer of stockholder approval of the Issuer's Fourth Amended and Restated 2008 Stock Incentive Plan. On May 22, 2014, the award was granted upon the stockholders' approval of the Issuer's Fourth Amended and Restated 2008 Stock Incentive Plan. On May 22, 2014, the award was granted upon the stockholders' approval of the Issuer's Fourth Amended and Restated 2008 Stock Incentive Plan at the Issuer's 2014 annual meeting of stockholders.

2. On July 12, 2013, the Board of Directors of the Issuer approved the grant of options to purchase the Issuer's common stock at an exercise price of \$6.36, the closing price of the Company's common stock on The NASDAQ Global Market on July 12, 2013, as adjusted to reflect the one-for-six reverse stock split effected on July 17, 2013. The award was made contingent upon receipt by the Issuer of stockholder approval of the Issuer's Fourth Amended and Restated 2008 Stock Incentive Plan. On May 22, 2014, the award was granted upon the stockholders' approval of the Issuer's Fourth Amended and Restated 2008 Stock Incentive Plan at the Issuer's 2014 annual meeting of stockholders.

3. The options vest in an equal annual amount over a four-year period beginning on the first anniversary of the grant date.

/s/	Jane	Α.	Me	y <u>er</u> ,	as	<u>attorney</u>	
	fact						

<u>05/27/2014</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.